Beneath the spotlights of the Beijing studio, Mr. Lv Zhonghua and Ms. Huang Minhua, Co‑founders of Aoyikang Medical Technology (Wuxi) Co., Ltd., drew upon over 30 years of sincerity and dedication in medical‑technology R&D as they recounted the company’s innovative journey: from breakthroughs in minimally‑invasive anorectal treatment to strategic expansion into the women’s‑health sector.
This Wuxi‑based medical‑device enterprise operates on a dual‑driven model of “proprietary‑technology innovation coupled with clinical‑demand orientation”. Its clinically tailored instruments, fine‑tuned for Chinese clinical practices, pave the way for more comfortable patient recovery. Through solid technological innovation, it demonstrates the prowess of China‑developed medical solutions on the global healthcare arena.
“What foreign counterparts can accomplish, we Chinese can not only achieve, but also deliver outcomes better suited to our local clinical realities.”
Mr. Lv Zhonghua’s founding vision took root in his exposure to medical devices back in the 1980s, as well as his firsthand observation of the prolonged recovery and suffering inflicted by conventional surgeries. A dedicated craftsman with more than 30 years of front‑line industry experience, he has been fascinated by invention since childhood. In his early days, he experimented with developing products such as earphones and blood detectors, pouring all his spare funds into R&D. After witnessing the drawbacks of traditional surgical procedures, the idea of creating “more human‑centered, agile medical tools” began to take shape, eventually leading to the birth of Aoyikang.
From its founding, Aoyikang has focused on two people‑centered healthcare segments: anorectal disorders and women’s health. Guided by its core philosophy of precision, simplicity, efficiency and safety, the company rejects copycat imitation and stays committed to the “difficult yet worthwhile path”. Ms. Huang Minhua, Co‑founder, leads the team to prioritize real‑world clinical challenges. The team developed the world‑first minimally‑invasive hemorrhoid ligation‑anastomosis device, enabling “one instrument to complete an entire surgery” and revolutionizing conventional anorectal surgical workflows. Looking further ahead, the company proactively ventured into women’s health and initiated proprietary medical‑device R&D to tackle HPV infection, a global public‑health threat.
Medical innovation is a “long‑distance race of trust”. Aoyikang has followed a long‑term, resolute path from conceptual design to market acceptance. Twenty years ago, most domestic medical‑device enterprises focused on imitation and incremental improvement. When Aoyikang set out to develop anastomosis devices with entirely new structural concepts, its greatest challenge was not technical capability, but gaining trust from clinicians.
To break the stereotype that “domestic products are inferior to imported alternatives”, Lv Zhonghua and his team immersed themselves in front‑line clinical settings. They held repeated discussions with clinicians, dissected operational pain points, and re‑engineered instrument structures and force‑transmission mechanisms beyond conventional design frameworks. After the product launch, it went from drawing little attention at trade shows to attracting active engagement from physicians, and from tentative trials to accumulating substantial clinical feedback. Every step embodies unwavering commitment to quality. On one occasion, senior experts raised safety concerns over new materials. The team brought biocompatibility reports, fatigue‑test data and dissected product samples for a three‑hour face‑to‑face discussion. They conducted point‑by‑point analysis and repeated demonstrations to address concerns with transparency and sincerity.
Such perseverance anchored in clinical value has earned Aoyikang growing recognition. To tackle core challenges posed by HPV infection, the team completed systematic screening and parameter optimization to finalize the core composition and synthesis process for its HPV therapeutic rod. Combining specialized materials with precise field‑intensity coordination, the product inhibits viral replication and accelerates virus clearance. Clinical validations show an HPV clearance rate of 94%, alongside proven inhibitory effects on early‑stage cervical cancer cells. It represents a therapeutic paradigm shift from “passive lesion management” to “active virus elimination”.
Today, Aoyikang has built solid technological moats, holding 11 domestic patents and 2 software copyrights. Its hot‑compress plasters and other products have obtained Class‑II medical device registration certificates, establishing the company as an innovation benchmark in the medical‑technology sector.
The synergy of “proprietary‑technology‑driven innovation” and “clinical‑demand‑oriented R&D” constitutes Aoyikang’s core competitive advantage for sustained growth. According to Mr. Lv Zhonghua, the company adheres to the principle of “from clinic, for clinic”. It translates expert advice into innovative inspiration and delivers products to resolve real‑world clinical challenges. For example, the anorectal therapeutic instrument integrates red‑light physiotherapy, biological vibration and postoperative anal dilation functions. It delivers multi‑dimensional therapeutic effects in a single session, boosting clinical efficacy while improving patient experience — a perfect embodiment of Aoyikang’s innovation philosophy.
As a private enterprise, Aoyikang benefits from rapid response and agile decision‑making. It sensitively captures clinical feedback and iterates products in a timely manner. Supported by Wuxi’s industrial ecosystem and R&D resources, the company continuously optimizes manufacturing processes to enhance product quality. It also attracts a cohort of aspiring and talented technical professionals to build an open medical‑innovation platform.
Looking ahead, Aoyikang has mapped out a clear development blueprint. In the short term, it will accelerate the registration and commercial roll‑out of the HPV therapeutic rod, advance the launch of new‑generation intelligent minimally‑invasive devices, and consolidate its leading position in anorectal treatment. In the medium term, it will foster a dual‑wheel ecosystem built around the “Minimally‑Invasive Technology Platform” and the “Gynecological Physical Therapy Platform”, satisfy multi‑department clinical demands, and provide holistic solutions covering diagnosis through rehabilitation. In the long run, the enterprise aims to become a highly respected global medical‑device leader in anorectal care and women’s health. It will engage with capital markets, share development gains with its team, and enable China‑originated medical technologies to serve more patients worldwide.
From its R&D base in Huishan District, Wuxi to the spotlight of the Beijing studio, Aoyikang embodies its mission of “Safeguarding Quality of Life Through Technology” through more than 30 years of perseverance. Going forward, this people‑livelihood‑focused medical enterprise will continue to take proprietary technology as its spear and clinical demands as its sail. It will project an even stronger Chinese voice onto the global healthcare arena and bring health and hope to greater numbers of patients.